GOLDEN, Colo. – September 1, 2015 – Today, PharmaJet, the maker of innovative, needle-free injector technology, announced a partnership with ABO Pharmaceuticals, a leader in the flu vaccine distribution market and a worldwide distributor of biological and pharmaceutical products. Through this arrangement, ABO Pharmaceuticals is offering the PharmaJet Needle-Free Injection System for needle-free flu shots1 throughout the United States. The product is currently available for the 2015/16 flu season.
ABO Pharmaceuticals’ specialty flu vaccine and product distribution program, referred to as “Got Flu,” aims to offer the fastest, most convenient and most affordable products.
“Entering the market this year, the PharmaJet Needle-Free Injector has been well received by patients and health care providers alike. In fact, 93 percent of patients and 87 percent of health care providers reported that they would choose the Pharmajet needle-free option again for the upcoming flu season,” said Ron Lowy, PharmaJet Chairman and CEO. “We are excited to partner with ABO to assist in our nationwide rollout of PharmaJet Needle-Free flu shots, and we anticipate that the increased availability of the device will enable greater vaccination compliance.”
1Refer to Instructions for Use and the individual device & drug/biologic labeling for prescribing information to ensure safe injections and to review
About PharmaJet, Inc.
Based in Golden, Colorado, PharmaJet was founded with the goal of reducing the use of medical needles throughout the world. PharmaJet’s innovative Stratis® Injector has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. In August 2014, the PharmaJet Needle-Free Injector was approved for delivery of an influenza vaccine to deliver needle-free flu shots. The PharmaJet Needle-Free Injector is easy-to-use and eliminates needlestick injuries, needle reuse and cross contamination, and helps reduce sharps waste disposal.